Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of veterinary pharmacology and therapeutics"
DOI: 10.1111/jvp.12980
Abstract: Cytosine arabinoside (CA) is a commonly used treatment for dogs with meningoencephalomyelitis of unknown aetiology (MUE) with various proposed protocols, many requiring 24 hours (h) of hospitalization or two visits within 24 h. This is a unidirectional… read more here.
Keywords: meningoencephalomyelitis unknown; unknown aetiology; range; subcutaneous protocol ... See more keywords
Cytosine arabinoside constant rate infusion without subsequent subcutaneous injections for the treatment of dogs with meningoencephalomyelitis of unknown origin
Sign Up to like & getrecommendations! Published in 2020 at "Veterinary Record"
DOI: 10.1136/vr.106019
Abstract: Background The administration of cytosine arabinoside (CA) by continuous rate infusion (CRI) at the time of diagnosis has been shown to improve the 3-month survival of dogs diagnosed with meningoencephalomyelitis of unknown origin (MUO), compared… read more here.
Keywords: meningoencephalomyelitis unknown; subcutaneous injections; unknown origin; rate infusion ... See more keywords